EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

MyD88 and Its Inhibitors in Cancer: Prospects and Challenges

Jiali Song, Yuying Li, Ke Wu, Yan Hu, Luo Fang

Biomolecules · 2024

DOI: 10.3390/biom14050562 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2024. Verfasst von Jiali Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China. Hauptthemen laut MEDLINE: Myeloid Differentiation Factor 88, Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation, Zhejiang Pharmaceutical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The interplay between the immune system and cancer underscores the central role of immunotherapy in cancer treatment. In this context, the innate immune system plays a critical role in preventing tumor invasion. Myeloid differentiation factor 88 (MyD88) is crucial for innate immunity, and activation of MyD88 promotes the production of inflammatory cytokines and induces infiltration, polarization, and immune escape of immune cells in the tumor microenvironment. Additionally, abnormal MyD88 signaling induces tumor cell proliferation and metastasis, which are closely associated with poor prognosis. Therefore, MyD88 could serve as a novel tumor biomarker and is a promising target for cancer therapy. Current strategies targeting MyD88 including inhibition of signaling pathways and protein multimerization, have made substantial progress, especially in inflammatory diseases and chronic inflammation-induced cancers. However, the specific role of MyD88 in regulating tumor immunity and tumorigenic mechanisms remains unclear. Therefore, this review describes the involvement of MyD88 in tumor immune escape and disease therapy. In addition, classical and non-classical MyD88 inhibitors were collated to provide insights into potential cancer treatment strategies. Despite several challenges and complexities, targeting MyD88 is a promising avenue for improving cancer treatment and has the potential to revolutionize patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid Differentiation Factor 88NeoplasmsHumansAnimalsTumor MicroenvironmentSignal TransductionAntineoplastic AgentsImmunity, InnateImmunotherapy

Stichwörter der Autor:innen

MyD88cancerimmune escapeinhibitorstumor markers

Substanzen

Myeloid Differentiation Factor 88MYD88 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
  • Ruian People's Hospital, Wenzhou Medical College Affiliated Third Hospital, Wenzhou 325000, China.

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Provincial Natural Science Foundation
  • Zhejiang Pharmaceutical Association
  • Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China
  • Zhejiang Pharmaceutical Society Hospital pharmacy special research project

Zitieren

APA

Song, J., Li, Y., Wu, K., Hu, Y., & Fang, L. (2024). MyD88 and Its Inhibitors in Cancer: Prospects and Challenges. Biomolecules. https://doi.org/10.3390/biom14050562

Vancouver

Song J, Li Y, Wu K, Hu Y, Fang L. MyD88 and Its Inhibitors in Cancer: Prospects and Challenges. Biomolecules. 2024. doi:10.3390/biom14050562

BibTeX
@article{Song2024,
  author = {Song, Jiali and Li, Yuying and Wu, Ke and Hu, Yan and Fang, Luo},
  title = {MyD88 and Its Inhibitors in Cancer: Prospects and Challenges},
  journal = {Biomolecules},
  year = {2024},
  doi = {10.3390/biom14050562}
}
Kostenlos starten →